Insight

Sep 2, 2024, 17:22

Carmine Valenza: The role of gBRCA-PV in post-PARPi myeloid neoplasms, in patients with ovarian cancer

Carmine Valenza, MPH Student at Harvard T.H. Chan School of Public Health, shared a post on X:

“Just out on ESMO Open our last contribution on the role of gBRCA-PV in post-PARPi myeloid neoplasms, in patients with ovarian cancer.

In heavily pretreated patients, gBRCA impact seems to be even higher than PARPi exposure .

Thanks to all the coauthors!

Authors: C.Valenza , M. Mongillo, F.Gigli, D.Trapani, J.Katrini, E.Nicolò, L.Boldrini, L.Boscolo Bielo, G.Castellano, L.Guidi, G.Pellizzari, S.Derio,M.Lapresa, G.Parma, E.Derenzini, G.Curigliano, N.Colombo.

Carmine Valenza: The role of gBRCA-PV in post-PARPi myeloid neoplasms, in patients with ovarian cancer

Source: Carmine Valenza/X

cancer Carmine Valenza D. Trapani E.Derenzini E.Nicolò ESMO Open F.Gigli G Curigliano G.Castellano G.Parma G.Pellizzari gBRCA-PV J.Katrini L. Boscolo Bielo L.Boldrini L.Guidi M. Mongillo M.Lapresa N.Colombo. OncoDaily Oncology Ovarian Cancer post-PARPi myeloid neoplasms S.Derio

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage